Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach - Asian perspective

Oncology

Volumn 78, Issue SUPPL. 1, 2010, Pages 167-171

  Lee, Jung Min ^a   Han, Kwang Hyub ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Hepatocellular carcinoma, advanced stage; Sorafenib

Indexed keywords

AEG 35156; CAPECITABINE; ERLOTINIB; OXALIPLATIN; PLACEBO; SORAFENIB; SUNITINIB; UFT;

ADVANCED CANCER; ALOPECIA; ASIA; CANCER INVASION; CANCER SURVIVAL; CLINICAL TRIAL; CONSENSUS; DESQUAMATION; DIARRHEA; DRUG COST; DRUG INDICATION; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; NAUSEA; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW;

ALGORITHMS; ASIA; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; HUMANS; LIVER NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 77954474120     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315246     Document Type: Review

References (35)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
3. Kim SR, Kudo M, Hino O, Han KH, Chung YH, Lee HS, Organizing Committee of Japan- Korea Liver, Symposium: Epidemiology of hepatocellular carcinoma in Japan and Korea. A review. Oncology 2008; 75(suppl 1):13-16.
4. Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J: Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol 2005; 100: 1995-2004.
5. Han KH, Lee JT, Seong J: Treatment of nonresectable hepatocellular carcinoma. J Gastroenterol Hepatol 2002; 17(suppl 3):S424-S427.
6. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
7. Simonetti RG, Liberati A, Angiolini C, Pagliaro L: Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997; 8: 117-136.
8. Chung YH, Song IH, Song BC, Lee GC, Koh MS, Yoon HK, Lee YS, Sung KB, Suh DJ: Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon- alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000; 88: 1986-1991.
9. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K, Sata M: Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95: 588-595.
10. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, Tang A, Johnson PJ: A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/ fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97: 1532-1538.
11. Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin JD, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, Gruenberger T, Haller D, Haustermans K, Hoff P, Kerr D, Labianca R, Moore M, Nordlinger B, Ohtsu A, Rougier P, Scheithauer W, Schmoll HJ, Sobrero A, Tabernero J, van de Velde C: The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol 2009; 20(suppl 7):vii1-vii6.
12. Wilhelm S, Chien DS: Bay 43-9006: preclinical data. Curr Pharm Des 2002; 8: 2255-2257.
13. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
14. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M: Bay 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006; 98: 326-334.
15. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, Sharp Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
16. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
17. Lee HC: Systemic chemotherapy of hepatocellular carcinoma - Korean experience. Oncology 2008; 75(suppl 1):114-118.
18. Shim JH, Park JW, Choi JI, Park BJ, Kim CM: Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a hepatitis B virus-endemic area. J Cancer Res Clin Oncol 2009; 135: 617-625.
19. Yau T, Chan P, Ng KK, Chok SH, Cheung TT, Fan ST, Poon RT: Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis Bendemic Asian population: presence of lung metastasis predicts poor response. Cancer 2009; 115: 428-436.
20. Park KW, Park JW, Choi JI, Kim TH, Kim SH, Park HS, Lee WJ, Park SJ, Hong EK, Kim CM: Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus- endemic area. J Gastroenterol Hepatol 2008; 23: 467-473.
21. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28: 751-755.
22. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, Bru C, Rodes J, Bruix J: Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29: 62-67.
23. Kang YK, Guan Z, Chen Z, Tsao CJ, Qin S, Kim JS, Burock K, Zou J, Voliotis D, Cheng AL: Sorafenib is effective in patients from the Asia-Pacific region with hepatocellular carcinoma (HCC): subgroup analysis of effect of macroscopic vascular invasion, extrahepatic spread, and ECOG performance status on outcome. Hepatology 2008; 48: 976A.
24. Sherman M, Mazzaferro V, Amadori D, Seitz J, Moscovici M, Shan M, Nadel A, Voliotis D, Llovet JM, Bruix J, on behalf of the SHARP investigators study group: Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and vascular invasion or extrahepatic spread: a subanalysis from the SHARP trial (abstract). J Clin Oncol 2008; 26(suppl):4584.
25. Colombo M: Sorafenib in advanced hepatocellular carcinoma: a further step toward personalized therapy of liver cancer. Gastroenterology 2009; 136: 1832-1835.
26. Muszbek N, Shah S, Carroll S, McDonald H, Dale P, Maroun J, Knox J: Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada. Curr Med Res Opin 2008; 24: 3559-3569.
27. Nadler E, Eckert B, Neumann PJ: Do oncologists believe new cancer drugs offer good value? Oncologist 2006; 11: 90-95.
28. Yau T, Chan P, Epstein R, Poon RT: Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int 2009; 29: 10-17.
29. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
30. Hsieh CH, Jeng KS, Lin CC, Chen CK, Liu CY, Lin CP, Tai HC, Wang CH, Shueng PW, Chen YJ: Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma. Clin Drug Investig 2009; 29: 65-71.
31. Greten TF, Korangy F, Manns MP, Malek NP: Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer 2009; 100: 19-23.
32. Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, Huang XW, Tang ZY: Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res 2008; 14: 5124-5130.
33. Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Thng CH, Chow P, Ong HS, Chung A, Soo KC: Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med 2009; 13: 2673-2683.
34. Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW, Lee do Y, Chon CY, Moon YM, Han KH: Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007; 110: 129-137.
35. Han KH, Seong J, Kim JK, Ahn SH, Lee do Y, Chon CY: Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2008; 113: 995-1003.